JP2022525121A5 - - Google Patents

Info

Publication number
JP2022525121A5
JP2022525121A5 JP2021555034A JP2021555034A JP2022525121A5 JP 2022525121 A5 JP2022525121 A5 JP 2022525121A5 JP 2021555034 A JP2021555034 A JP 2021555034A JP 2021555034 A JP2021555034 A JP 2021555034A JP 2022525121 A5 JP2022525121 A5 JP 2022525121A5
Authority
JP
Japan
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
compound according
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021555034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525121A (ja
Filing date
Publication date
Priority claimed from GBGB1902490.0A external-priority patent/GB201902490D0/en
Application filed filed Critical
Publication of JP2022525121A publication Critical patent/JP2022525121A/ja
Publication of JP2022525121A5 publication Critical patent/JP2022525121A5/ja
Pending legal-status Critical Current

Links

JP2021555034A 2019-02-25 2020-02-17 Paskの阻害剤としてのピラゾロピリジン誘導体 Pending JP2022525121A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1902490.0 2019-02-25
GBGB1902490.0A GB201902490D0 (en) 2019-02-25 2019-02-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
PCT/EP2020/054122 WO2020173739A1 (en) 2019-02-25 2020-02-17 Pyrazolopyridine derivatives as inhibitors of pask

Publications (2)

Publication Number Publication Date
JP2022525121A JP2022525121A (ja) 2022-05-11
JP2022525121A5 true JP2022525121A5 (cg-RX-API-DMAC7.html) 2023-02-20

Family

ID=65998935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021555034A Pending JP2022525121A (ja) 2019-02-25 2020-02-17 Paskの阻害剤としてのピラゾロピリジン誘導体

Country Status (19)

Country Link
US (1) US20220144823A1 (cg-RX-API-DMAC7.html)
EP (1) EP3931191B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022525121A (cg-RX-API-DMAC7.html)
KR (1) KR20210134001A (cg-RX-API-DMAC7.html)
CN (1) CN113474344A (cg-RX-API-DMAC7.html)
AR (1) AR124749A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020229041A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021016642A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130154A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021010485A2 (cg-RX-API-DMAC7.html)
ES (1) ES2963409T3 (cg-RX-API-DMAC7.html)
GB (1) GB201902490D0 (cg-RX-API-DMAC7.html)
IL (1) IL285751A (cg-RX-API-DMAC7.html)
MA (1) MA55074A (cg-RX-API-DMAC7.html)
MX (1) MX2021010093A (cg-RX-API-DMAC7.html)
PH (1) PH12021552032A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109157TA (cg-RX-API-DMAC7.html)
TW (1) TW202045505A (cg-RX-API-DMAC7.html)
WO (1) WO2020173739A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022070288A1 (ja) * 2020-09-30 2022-04-07 旭化成ファーマ株式会社 含窒素二環化合物
WO2025143152A1 (ja) * 2023-12-27 2025-07-03 全薬工業株式会社 チアゾリル-ピラゾロ[1,5-a]ピリジン化合物、およびそのMYLK4阻害剤としての使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2048142A3 (en) * 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
CA2732520A1 (en) * 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
JP2012516329A (ja) * 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ, インコーポレイテッド Pi3k阻害剤としてのヘテロアリールおよびその使用
WO2014066795A1 (en) * 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
EP3227286B1 (de) * 2014-12-02 2018-12-26 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
JP7175917B2 (ja) * 2017-04-27 2022-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 新規のalk2阻害剤及びbmpシグナル伝達の阻害方法

Similar Documents

Publication Publication Date Title
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
KR102153772B1 (ko) 아릴 에테르 및 이의 용도
AU658441B2 (en) Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
JP5765739B2 (ja) ロスバスタチンラクトールの薬物としての使用
IL272115B (en) An aryl-phosphorus-oxygen compound as an egfr kinase inhibitor
JP2022512482A5 (cg-RX-API-DMAC7.html)
JP7209897B2 (ja) Crbnタンパク質モジュレーターとしての二環式化合物
IL286839B (en) Propyne-indole compounds
JP2006515858A5 (cg-RX-API-DMAC7.html)
JP2011037841A5 (cg-RX-API-DMAC7.html)
JP2022526553A5 (cg-RX-API-DMAC7.html)
CN106831570B (zh) 喹啉类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途
JP2013518881A5 (cg-RX-API-DMAC7.html)
JP2004506718A5 (cg-RX-API-DMAC7.html)
HRP20150273T1 (hr) Spojevi bis(floroalkil)-1,4-benzodiazepinona
JP2009537469A5 (cg-RX-API-DMAC7.html)
JP2005511547A5 (cg-RX-API-DMAC7.html)
HUT66159A (en) Pyridopyrimidine derivatives, pharmaceutical compositions containing them and process for their production
JP7665774B2 (ja) 二環式フェノール系化合物及びその使用
JP2024536863A5 (cg-RX-API-DMAC7.html)
JP2024540164A5 (cg-RX-API-DMAC7.html)
JP2006523698A5 (cg-RX-API-DMAC7.html)
WO2025189008A1 (en) Methods of treating cftr-mediated diseases or disorders
WO2001062708A1 (fr) Derives d'acide benzoique, procede de production desdits derives, et medicament contenant ces derives comme principe actif
RU2006111458A (ru) Фармацевтические композиции, содержащие малонамидные производные для уменьшения продукции кожного сала